QTTB · Q32 Bio Inc.
Market Cap
$261.08M
Shares
29.77M
Volume · Oct 5
456.31K
Avg daily vol (3M)
1.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.23
Open$8.35
Day$8.17–9.11
52W close$1.93–21.38
Avg vol 30d923K
Short int3.8M · 12.7% float · 5.2d
Short vol78%
Last earningsJul 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
$33.79M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
31.5%
Trailing 12 months
P / E (TTM)
2.6
Trailing earnings · reciprocal yield 37.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+66.8%
Year over year · more shares
Price change (1Y)
+297.6%
Trailing year
Short interest
12.7%
Latest settlement · 5.2 days to cover
AI Brief
Q2 FY26 earnings call · Jul 13, 2026
Q2 FY26
TL;DR. Q32 Bio reported positive 36-week Part B SIGNAL-AA topline results for bempikibart in alopecia areata and plans to initiate a registration-directed program in 1H 2027; the company also completed a $200 million public offering, extending cash runway through Phase 3 topline results.
Bullish
- + Bempikibart achieved a 35.3% mean SALT reduction and 40% SALT-20 response at Week 36 in Part B, with a well-tolerated safety profile.
- + Company plans to initiate a registration-directed Phase 3 program in severe/very severe AA in 1H 2027.
- + Completed $200 million public offering, extending cash runway through Phase 3 topline results.
- + Part B OLE enrollment ongoing, with potential for monthly/bi-monthly/quarterly maintenance dosing.
- + R&D expenses declined to $4.3M from $5.2M YoY, reflecting lower ADX-097 spend.
Bearish
- − G&A expenses rose to $4.9M from $4.0M YoY on higher stock-based compensation.
- − Company reported a Q2 net loss of $8.9M ($0.44/share).
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−38%
below
RSI (14)
24
oversold
MACD trend
Negative
52-week position
32%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−36%
trailing
6-month return
+52%
trailing
YTD return
+148%
this year
Relative strength
+40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +27 funds added
Insider flow
Distributing
Net -$275.1K over 90 days · 100% sells
Short interest
Rising
12.67% of float · ▲ +6.1% MoM · 5.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
72 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+137%
Y/Y
Free cash flow
$-33.5M
Valuation
P/E 65.4
rich
Quant / Vol
risk profile
Volatility
175%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
10.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
24
Neutral
MACD trend
Negative
Bearish
52-week position
32%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +27 funds added
Insider flow
Distributing
Net -$275.1K over 90 days · 100% sells
Short interest
Rising
12.67% of float · ▲ +6.1% MoM · 5.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
72 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $8 · 32%
Range high $21
vs 200-day avg -6%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QTTB
this stock
Q32 Bio Inc.
|
$261.08M | +147.9% | -64.0% | 65.4 | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QTTB | -6.2% | -35.7% | +52.1% | -0.5% | +147.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.9% | -35.2% | +40.0% | -1.4% | +135.0% |